| A Trial of Tarlatamab in Patients With Pretreated Extensive-stage Small Cell Lung Cancer (ES-SCLC) and ECOG PS 2 (NCT07203053) | ETOP IBCSG Partners Foundation | 2026-04-15 |
| A Clinical Study to Assess the Efficacy of Adjuvant Immunotherapy With Cemiplimab in Patients With Surgically Removed Non-small Cell Lung Cancer Who Have Not Received Prior Chemotherapy (NCT06931717) | ETOP IBCSG Partners Foundation | 2026-01-12 |
| AMG510 (sotorasib) Plus Lenvatinib As Second-line Treatment in Patients with KRASG12C Mutant, Metastatic NSCLC (NCT06068153) | ETOP IBCSG Partners Foundation | 2025-03-01 |
| A Study to Evaluate the Benefit of Adding Durvalumab After Chemotherapy, Durvalumab and Surgery in Patients With Early-stage, Operable, Non-small Cell Lung Cancer. (NCT06284317) | ETOP IBCSG Partners Foundation | 2025-01-15 |
| Brigatinib Post Definitive Chemo-radiotherapy in Patients with ALK-fusion Non-small Cell Lung Cancer (NCT05718297) | ETOP IBCSG Partners Foundation | 2024-06-07 |
| A Window-of-Opportunity Trial of Giredestrant +/- Triptorelin vs. Anastrozole + Triptorelin in Premenopausal Patients With ER-positive/HER2-negative Early Breast Cancer (NCT05896566) | ETOP IBCSG Partners Foundation | 2024-01-23 |
| Niraparib Added to Anti-PD-L1 Antibody Maintenance in SLFN11-positive, Extensive-disease SCLC (NCT05718323) | ETOP IBCSG Partners Foundation | 2023-12-20 |
| Adagrasib in Patients With KRASG12C-mutant NSCLC Who Are Elderly or Have Poor Performance Status (NCT05673187) | ETOP IBCSG Partners Foundation | 2023-06-12 |
| Amivantamab, Lazertinib and Bevacizumab in Patients With EGFR-mutant Advanced Non-small Cell Lung Cancer With Progression on Previous Third-generation EGFR-TKI (NCT05601973) | ETOP IBCSG Partners Foundation | 2023-03-27 |
| Immunotherapy or Targeted Therapy With or Without Stereotactic Radiosurgery for Patients With Brain Metastases From Melanoma or Non-small Cell Lung Cancer (NCT05522660) | ETOP IBCSG Partners Foundation | 2022-11-30 |
| Osimertinib and Locally Ablative Radiotherapy in Patients With Synchronous Oligo-metastatic EGFR Mutant NSCLC (STEREO) (NCT04908956) | ETOP IBCSG Partners Foundation | 2022-08-04 |
| ABC-lung: Atezolizumab, Bevacizumab and Chemotherapy in EGFR-mutant Non-small Cell Lung Carcinoma (NCT04245085) | ETOP IBCSG Partners Foundation | 2020-09-29 |
| Immunotherapy, Chemotherapy, Radiotherapy and Surgery for Synchronous Oligo-metastatic NSCLC (NCT03965468) | ETOP IBCSG Partners Foundation | 2019-11-19 |
| Palbociclib for HR Positive / HER2-negative Isolated Locoregional Recurrence of Breast Cancer (NCT03820830) | ETOP IBCSG Partners Foundation | 2019-08-27 |
| To Reduce the Use of Chemotherapy in Postmenopausal Patients With ER-positive and HER2-positive Breast Cancer (TOUCH) (NCT03644186) | ETOP IBCSG Partners Foundation | 2019-04-16 |
| ALEctinib for the Treatment of Pretreated RET-rearranged Advanced Non-small Cell Lung Cancer (NCT03445000) | ETOP IBCSG Partners Foundation | 2018-11-06 |
| MEtronomic TrEatment Option in Advanced bReast cAncer (NCT02954055) | ETOP IBCSG Partners Foundation | 2017-09-13 |
| PembROlizuMab Immunotherapy Versus Standard Chemotherapy for Advanced prE-treated Malignant Pleural Mesothelioma (NCT02991482) | ETOP IBCSG Partners Foundation | 2017-09-12 |